Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13127864 | 1.00 | KMT2A (0.39) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7806892 | 0.97 | KDM4E (0.40) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23240873 | 0.92 | — | — | |
| SCHEMBL8301886 | 0.87 | — | — | |
| SCHEMBL2837316 | 0.82 | KMT2A (0.40) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL1226520 | 0.80 | KMT2A (0.39) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL1226467 | 0.80 | KMT2A (0.39) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| Bromide SCHEMBL16057314 | 0.80 | KMT2A (0.39) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1226440 | 0.79 | KDM4E (0.41) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL18122821 | 0.78 | KDM4E (0.63) | KMT2AKDM4EALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11008366-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120264693-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2012-10-18 | — | — | US | disclosed |
| US-20120264693-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2012-10-18 | — | — | US | disclosed |
| WO-2010142293-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| EP-2260859-A1 | Compounds acting as peptide gap junction modulators and their uses | Zealand Pharma A/S (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | KMT2A 3419/4885KDM4E 4317/4885ALDH1A1 4716/4885 |
| US-20120264693-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | GJA1, GJB2, GAP43 | KMT2A 4875/4885KDM4E 4798/4885ALDH1A1 4600/4885 |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885KDM4E 3750/4885ALDH1A1 2219/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | KMT2A 3834/4885KDM4E 3330/4885ALDH1A1 302/4885 |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | ILK, EPCAM, MMP8 | KMT2A 2741/4885KDM4E 2617/4885ALDH1A1 1432/4885 |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | KMT2A 3776/4885KDM4E 4076/4885ALDH1A1 2824/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | KMT2A 3419/4885KDM4E 4317/4885ALDH1A1 4716/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | KMT2A 3973/4885KDM4E 4575/4885ALDH1A1 4687/4885 |
| US-11008366-B2 | Peptidomimetic macrocycles | GLP1R, PROKR1, VIP | KMT2A 4189/4885KDM4E 4706/4885ALDH1A1 4756/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | KMT2A 3763/4885KDM4E 4259/4885ALDH1A1 4843/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885KDM4E 3750/4885ALDH1A1 2219/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885KDM4E 3750/4885ALDH1A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.